Genenta Science S.p.A. (GNTA)

NASDAQ: GNTA · IEX Real-Time Price · USD
-0.40 (-5.84%)
May 24, 2022 3:45 PM EDT - Market closed

Company Description

Genenta Science is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors.

We have developed a novel biologic platform which involves the ex-vivo gene transfer of a therapeutic candidate into autologous hematopoietic stem/progenitor cells (HSPCs) to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages (Tie2 Expressing Monocytes - TEMs).

Our technology is designed to turn TEMs, which normally have an affinity for and travel to tumors, into a “Trojan Horse” to counteract cancer progression and to prevent tumor relapse.

Our technology is not target dependent, and therefore we believe it can be used as a treatment for a broad variety of cancers. Our lead product candidate, Temferon, was developed using our platform and carries an interferon-alpha (IFN-α) payload.

Because Temferon delivers the IFN-α payload directly to the tumor, we believe it will demonstrate clinical activity without the side effect profile of systemic delivery of IFN-α.

We are currently conducting a Phase 1/2a dose-escalation clinical trial with Temferon in newly diagnosed uMGMT-GBM patients in Italy. We anticipate completing patient enrollment and treatment by the second quarter of 2022.

Genenta Science S.p.A.
IPO DateDec 15, 2021
SectorHealth Care
CEOPierluigi Paracchi

Contact Details

Via Olgettina No. 58
Milan 20132
Phone39 02 26 43 46 81

Stock Details

Ticker SymbolGNTA
Fiscal YearJanuary - December
Reporting CurrencyEUR
IPO Price$11.50
CIK Code1838716

Key Executives

Pierluigi ParacchiVice Chairman, Chief Executive Officer and GM
Dr. Luigi Naldini M.D., Ph.D.Co-Founder and Chairman of the Executive Scientific Board
Dr. Bernard Rudolph Gentner M.D.Founder and Member of the Executive Scientific Board
Richard B. SlanskyChief Financial Officer
Dr. Stefania Mazzoleni Ph.D.Scientific Project Manager and Communications Officer
Dr. Carlo Russo M.D.Chief Medical Officer and Head of Development

Latest SEC Filings

May 11, 20226-KReport of foreign issuer [Rules 13a-16 and 15d-16]
Apr 29, 202220-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]
Feb 25, 2022SC 13GStatement of acquisition of beneficial ownership by individuals
Feb 18, 2022SC 13GStatement of acquisition of beneficial ownership by individuals
Feb 14, 2022SC 13GStatement of acquisition of beneficial ownership by individuals
Dec 15, 2021424B1Prospectus [Rule 424(b)(1)]
Dec 15, 2021424B1Prospectus [Rule 424(b)(1)]
Dec 15, 2021EFFECTNotice of Effectiveness
Dec 14, 2021F-1MEFRegistration statement to add securities to prior Form F-1 registration [Rule 462(b)]
View All SEC Filings